BCAX insider files Rule 144 sale notice

BCAX insider Ryan Cohlhepp filed a Rule 144 notice to sell 149 shares of the company’s common stock through UBS Financial Services on or around 01/15/2026, with an aggregate market value of $2,684.98.

Rhea-AI Filing Summary

BCAX insider Ryan Cohlhepp filed a Rule 144 notice to sell 149 shares of the company’s common stock through UBS Financial Services on or around 01/15/2026, with an aggregate market value of $2,684.98. The filing reports that these shares were acquired on 05/12/2024 by exercising a stock option for cash. The notice indicates total common shares outstanding of 54,781,950, showing this planned sale is very small relative to the company’s share base.

Over the prior three months, Cohlhepp sold additional common shares in three equal blocks of 12,500 shares each on 10/15/2025, 11/21/2025, and 12/15/2025, with reported gross proceeds of $226,942.50, $225,587.50, and $233,547.50, respectively. The signer represents that he does not know of any undisclosed material adverse information about BCAX at the time of this notice.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction is disclosed for BCAX in this Form 144?

The notice reports that Ryan Cohlhepp intends to sell 149 shares of BCAX common stock through UBS Financial Services on or about 01/15/2026, with an aggregate market value of $2,684.98.

How were the BCAX shares in the planned Rule 144 sale acquired?

The 149 BCAX common shares were acquired on 05/12/2024 via an exercise of a stock option, with payment made in cash on the same date.

How many BCAX shares are reported as outstanding in this filing?

The Form 144 lists 54,781,950 BCAX common shares as outstanding in connection with the reported sale.

What BCAX insider sales occurred in the past three months before this notice?

The filing shows that Ryan Cohlhepp sold 12,500 BCAX common shares on each of 10/15/2025, 11/21/2025, and 12/15/2025, for gross proceeds of $226,942.50, $225,587.50, and $233,547.50, respectively.

On which exchange are the BCAX shares in this Form 144 to be sold?

The planned sale of 149 BCAX common shares is listed for trading on the NASDAQ exchange.

What representation does the insider make about BCAX’s information in this notice?

By signing the notice, the seller represents that he does not know any material adverse information about BCAX’s current or prospective operations that has not been publicly disclosed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/15/2026 - 04:03 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0002034665
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Bicara Therapeutics Inc.
SEC File Number	001-42271
Address of Issuer	116 HUNTINGTON AVENUE SUITE 703 BOSTON MASSACHUSETTS 02116
Phone	617-468-4219
Name of Person for Whose Account the Securities are To Be Sold	Cohlhepp Ryan
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	UBS Financial Services, Inc Eleven Madison Avenue 4th Floor New York NY 10010	149	2684.98	54781950	01/15/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	05/12/2024	Exercise of Stock Option	Issuer			149	05/12/2024	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Ryan Cohlhepp 116 HUNTINGTON AVENUE, SUITE 703 Boston MA 02116	Common	10/15/2025	12500	226942.50
Ryan Cohlhepp 116 HUNTINGTON AVENUE, SUITE 703 Boston MA 02116	Common	11/21/2025	12500	225587.50
Ryan Cohlhepp 116 HUNTINGTON AVENUE SUITE 703 Boston MA 02116	Common	12/15/2025	12500	233547.50

144: Remarks and Signature

Remarks
Date of Notice	01/15/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	02/12/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ UBS Financial Services Inc., as attorney-in-fact for Ryan Cohlhepp
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)